Short Interest Reporting: Cormedix Incorporated (NYSEMKT:CRMD) Sellers Covered 2.58% of Their Shorts

November 30, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Reporting: Cormedix Incorporated (NYSEMKT:CRMD) Sellers Covered 2.58% of Their Shorts

The stock of Cormedix Incorporated (NYSEMKT:CRMD) registered a decrease of 2.58% in short interest. CRMD’s total short interest was 3.83M shares in November as published by FINRA. Its down 2.58% from 3.93M shares, reported previously. With 153,100 shares average volume, it will take short sellers 25 days to cover their CRMD’s short positions. The short interest to Cormedix Incorporated’s float is 10.54%. About 6,835 shares traded hands. CorMedix Inc. (NYSEMKT:CRMD) has declined 60.00% since April 27, 2016 and is downtrending. It has underperformed by 65.23% the S&P500.

CorMedix Inc. is a commercial pharmaceutical and medical device company. The company has a market cap of $70.76 million. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It currently has negative earnings. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 , which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Insitutional Activity: The institutional sentiment increased to 0.64 in Q2 2016. Its up 0.10, from 0.54 in 2016Q1. The ratio improved, as 18 funds sold all CorMedix Inc. shares owned while 17 reduced positions. 10 funds bought stakes while 9 increased positions. They now own 4.22 million shares or 33.14% less from 6.32 million shares in 2016Q1.
Bridgeway Cap Management holds 0.01% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD) for 279,701 shares. Goldman Sachs Gp last reported 0% of its portfolio in the stock. Blackrock Institutional Trust Na reported 494,922 shares or 0% of all its holdings. The Massachusetts-based Bollard Grp Ltd Limited Liability Company has invested 0.07% in CorMedix Inc. (NYSEMKT:CRMD). Bnp Paribas Arbitrage has 0% invested in the company for 23 shares. Jpmorgan Chase And has 0% invested in the company for 14,704 shares. Blackrock Limited Liability Corp has invested 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD). Blackrock Advsr Ltd Liability owns 7,588 shares or 0% of their US portfolio. Vanguard Grp accumulated 1.11M shares or 0% of the stock. Susquehanna Grp Inc Llp holds 0% or 45,329 shares in its portfolio. Wells Fargo Mn owns 3,312 shares or 0% of their US portfolio. Ray Gerald L And holds 0.04% or 130,000 shares in its portfolio. Gp One Trading L P holds 0.01% or 303,325 shares in its portfolio. Deutsche Bancorporation Ag has invested 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD). Retail Bank Of America De holds 0% of its portfolio in CorMedix Inc. (NYSEMKT:CRMD) for 11,861 shares.

Insider Transactions: Since June 3, 2016, the stock had 4 buys, and 4 selling transactions for $1,643 net activity. On Friday, October 21 the insider Pfaffle Antony sold $44,600. TELLEZ CORA M also bought $21,588 worth of CorMedix Inc. (NYSEMKT:CRMD) on Friday, August 19. Another trade for 18,600 shares valued at $30,690 was bought by Markvicka Taunia. Duffy Matthew sold $126,008 worth of stock or 46,106 shares. Kaplan Myron also bought $34,496 worth of CorMedix Inc. (NYSEMKT:CRMD) shares.

CRMD Company Profile

CorMedix Inc., incorporated on July 28, 2006, is a commercial pharmaceutical and medical device company. The Firm in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Firm has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications.

Another recent and important CorMedix Inc. (NYSEMKT:CRMD) news was published by Valuewalk.com which published an article titled: “Resonant Down 70%… Could CorMedix Inc. (CRMD) Be Next?” on April 13, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>